About GT Biopharma
GT Biopharma is a company based in Washington (United States) founded in 1965 by Anthony Cataldo. The company has 1 employees as of December 31, 2024. GT Biopharma offers products and services including TriKE Therapies. GT Biopharma operates in a competitive market with competitors including Moderna, Merck, Roivant Sciences, BeiGene and AbbVie, among others.
- Headquarter Washington, United States
- Employees 1 as on 31 Dec, 2024
- Founders Anthony Cataldo
- Stage Public
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Gt Biopharma, Inc.
-
Annual Revenue
Not available
-
Net Profit
-$13.16 M (USD)-73.25as on Dec 31, 2024
-
EBITDA
-$14.36 M (USD)-5.8as on Dec 31, 2024
-
Latest Funding Round
$5.95 M (USD), Post-IPO
May 12, 2025
-
Investors
Not available
-
Employee Count
1
as on Dec 31, 2024
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of GT Biopharma
GT Biopharma is a publicly listed company on the NASDAQ with ticker symbol GTBP in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of GT Biopharma
GT Biopharma offers a comprehensive portfolio of products and services, including TriKE Therapies.
Biopharmaceutical agents that engage NK cells to target and kill cancer cells.
People of GT Biopharma
Unlock access to complete
Unlock access to complete
Funding Insights of GT Biopharma
Investments & Acquisitions by GT Biopharma
Investment portfolio details for GT Biopharma
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - GT Biopharma
Detailed financials for GT Biopharma
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Gt Biopharma Comparisons
Peer comparison for GT Biopharma
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of GT Biopharma
GT Biopharma operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Moderna, Merck, Roivant Sciences, BeiGene and AbbVie, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
mRNA-based therapeutics for diseases including cancer and infections are developed.
|
|
| Locked | Locked | Locked |
Pharmaceutical products are manufactured and marketed worldwide.
|
|
| Locked | Locked | Locked |
Therapeutics for neurology, oncology, rare, and endocrinology diseases are developed.
|
|
| Locked | Locked | Locked |
Targeted and immune-oncology drugs for cancer treatment are developed.
|
|
| Locked | Locked | Locked |
Biopharmaceutical research and drug development are conducted globally by AbbVie.
|
|
| Locked | Locked | Locked |
Developer of medicines to treat HIV/AIDS, liver diseases, cancer & others
|
Detailed competitors of GT Biopharma
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Gt Biopharma
Complete news archive for GT Biopharma
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about GT Biopharma
GT Biopharma was founded in 1965 and raised its 1st funding round 49 years after it was founded.
GT Biopharma is headquartered in Washington, United States. It is registered at Washington, District Of Columbia, United States.
As of Dec 31, 2024, the latest employee count at GT Biopharma is 1.
GT Biopharma was founded in 1965 and operates in the biotechnology sector, where immunotherapies are developed for cancer treatment. Proprietary platform technology is utilized to create biopharmaceutical drugs targeting conditions such as acute lymphocytic leukemia, non-Hodgkins lymphoma, acute myeloid leukemia, and various solid tumors. Operations focus on immuno-oncology advancements without specified geographic limitations.
GT Biopharma's top competitors include Merck, Moderna and Roivant Sciences.
GT Biopharma offers TriKE Therapies.
Yes, GT Biopharma is publicly traded on NASDAQ under the ticker symbol GTBP.
The ticker symbol of GT Biopharma is GTBP on NASDAQ.